Excalipoint Therapeutics develops targeted therapies that focus on modulating disease pathways at specific biological points.
Excalipoint Therapetics has raised $27.7M in total funding. The most recent round was Seed. The last funding was announced in March 2026.
Excalipoint Therapetics's investors include HSG, Matrix Partners China, 5Y Capital, Lilly Asia Ventures, BioVenture.
Excalipoint Therapetics is headquartered in Admiralty, Hong Kong.
Excalipoint Therapeutics develops targeted therapies that focus on modulating disease pathways at specific biological points.
Excalipoint Therapetics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Excalipoint Therapetics — Funding & Investors." VCBacked, March 18, 2026, https://www.vcbacked.co/company/excalipoint-therapetics. Accessed July 19, 2026.
VCBacked. (2026). Excalipoint Therapetics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/excalipoint-therapetics
{{cite web |title=Excalipoint Therapetics — Funding & Investors |url=https://www.vcbacked.co/company/excalipoint-therapetics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated